Image Image Image Image Image Image Image Image Image Image
Access
Up

Up

Help us put a stop to degenerative eye diseases. Collaborate with the BARCELONA MACULA FOUNDATION

Dr. Jordi Monés MD, PhDDirector

The Institut is the result of the passion and vocation of a team of people, led by Dr. Jordi Monés

+ Get to know the whole team

News + See all news items

Scientific1
10/07/2016.New scientific solutions for exudative AMD when conventional treatments do not work

The Institut de la Màcula performs diagnosis with indocyanine green angiography using a diode ...

News

LITE1
10/07/2016.The LITE path, a new dimension for diagnostic imaging

The Institut de la Màcula and the Institute of Photonic Sciences (...

News

20160620 Felipe Yagüe foto
20/06/2016.
Felipe Yagüe: «Es a medio plazo cuando el paciente con un diagnóstico irreversible se abre a las soluciones»

El responsable del servicio de atención psicológica del Institut de ...

News

Foto espurnes
15/06/2016.Enjoy St John’s Eve. Show foresight and protect your eyes

A special night is fast approaching. St John’s Eve is upon us and we want you all to enjoy it...

News

Blogs

Research + See all research

neovascularització coroidal
06/04/2016.Feeder vessel laser photocoagulation for idiopathic, subfoveal polypoidal choroidal vasculopaty not responding to eithelial growth factor therapy or photodynamic therapy

Dr. Jordi Monés, Dr. Josep Badal, Dr. Marc Biarnés. FEEDER VESSEL LASER PHOTOCOAGULATION FOR IDIOPATHIC, SUBFOVEAL POLYPOIDAL CHOROIDAL VASCULOPATHY NOT RESPONDING TO EITHER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY OR PHOTODYNAMIC THERAPY. Retin Cases Brief Rep. 2016 Winter;10(1):100-3. doi: 10.1097/ICB.0000000000000174.

http://www.ncbi.nlm.nih.gov/pubmed/26200385

PURPOSE:

To describe the management of a subfoveal polypoidal choroidal vasculopathy case refractory to antiangiogenic treatment and to photodynamic therapy.

METHODS:

Case report. A 65-year-old male patient presented with a diagnosis of exudative age-related macular degeneration of his left eye and unsuccessful response to eight antiangiogenic injections. Visual acuity was 20/33. Fluorescein angiography, spectral domain optical coherence tomography, and indocyanine green angiography confirmed the diagnosis of polypoidal choroidal vasculopathy. Two photodynamic therapy sessions along with two ranibizumab injections were performed, but no response was obtained. Identification and photocoagulation of the polyp feeder vessels was performed.

RESULTS

Polypoidal structures regressed, intraretinal and subretinal exudation resolved, and visual acuity was preserved with no adverse events.

CONCLUSION

Indocyanine green angiography-guided feeder vessel diode laser photocoagulation in selected cases of polypoidal choroidal vasculopathy may be considered an effective alternative therapy, especially in those refractory to both photodynamic therapy and antiangiogenic therapy.

...

Publication

Direct Visualization of a New Choroidal Vessel...
06/04/2016.Direct Visualization of a New Choroidal Vessel on Spectral-Domain Optical Coherence Tomography

Marc Biarnés, PhD; Jordi Monés, MD, PhD. Direct Visualization of a New Choroidal Vessel on Spectral-Domain Optical Coherence Tomography. Ophthalmic Images | March 10, 2016. JAMA Ophthalmol. 2016;134(3):e155017. doi:10.1001/jamaophthalmol.2015.5017.

http://archopht.jamanetwork.com/article.aspx?articleid=2500097

This Ophthalmic Image shows a new choroidal vessel on spectral-domain optical coherence tomography in a man in his 60s.

Spectral-domain optical coherence tomography detects choroidal neovascularization by its indirect effects on the retina.1 However, actual subretinal pigment epithelium (RPE) (type 1) or subretinal (type 2)2 new vessels often are not noted.

...

Publication

Foto Proxima A
31/03/2016.Proxima A: Epidemiological study of the progression of Geographic Atrophy secondary to Age-Related Macular Degeneration (GX29633)

If you are interested in taking part in a clinical trial, please fill in this form to contact us or call +34 935 950 155. 
Our team of professionals will answer you as soon as possible and we will assess whether you are eligible. 

Description

Prospective, multicentre epidemiological study of the progression of Geographic Atrophy secondary to Age-Related Macular Degeneration. This is an observational study which aims to recruit 360 patients with GA secondary to AMD. The population will have a higher number of patients showing positive results for the CFI biomarker profile by a proportion of 2:1.

The study’s duration will depend on the possible future availability of treatments approved for GA; if no treatment is approved, the expected maximum length of patient follow-up in this study is 48 months. Visual function and anatomical measurements will be taken on selection, at the basal moment (day 1) and then every 6 months.

Aims

The study’s principal aim is to learn more about the variability and the dynamic interval of visual function tests over time and the way these changes correlate with changes in the area of geographic atrophy (GA) in patients with GA secondary to age-related macular degeneration (AMD).

The secondary aims of this study are to assess the average variation with regard to the basal moment of the area of GA over time, assess the rates of a series of medical and ocular events of interest in the study patients, assess reading speed and variations over time in a series of results reported by the patients.

 Principal inclusion criteria

Patients older than 50 with GA secondary to AMD without signs of prior or active choroidal neovascularisation (NVC) in both eyes.

_MG_8162

 

If you are interested in taking part in a clinical trial, please fill in this form to contact us or call +34 935 950 155. 
Our team of professionals will answer you as soon as possible and we will assess whether you are eligible. 

...

Research Recruiting

FOTO Proxima B
31/03/2016.Proxima B: Epidemiological study of the progression of Geographic Atrophy secondary to Age-Related Macular Degeneration (GX29639)

Si quieres participar en esta investigación, llama a +34 93 595 01 55 o rellena este formulario.

Nuestro equipo de profesionales te informará y hará una primera evaluación de tu caso para determinar si eres elegible.

Descripción

Prospective, multicentre epidemiological study of the progression of Geographic Atrophy secondary to Age-Related Macular Degeneration.

This is an observational study which aims to recruit 200 patients with GA secondary to AMD. The expected maximum duration of patient follow-up in this study is 60 months. Visual function and anatomical measurements will be taken on selection, at the basal moment (day 1) and then every 6 months.

 Aims

The principal aims of this epidemiological study are to assess the progression of geographic atrophy (GA) through eye fundus autofluorescence (FAF) and to determine the prognostic value of the Complement Factor I (CFI) biomarker profile in the average variation of the GA area with regard to the basal moment.

This study’s secondary aims are to carry out assessments of the visual function and to assess variations over time in a series of results reported by the patients.

Principal inclusion criteria

Patients older than 50 with:

  •  Unilateral GA secondary to age-related macular degeneration (AMD).
  •  GA secondary to AMD in one eye and choroidal neovascularisation (NVC; active or treated) secondary to AMD in the contralateral eye.

_MG_8162

 

If you are interested in taking part in a clinical trial, please fill in this form to contact us or call +34 935 950 155. 
Our team of professionals will answer you as soon as possible and we will assess whether you are eligible. 

...

Research Recruiting

International patients

Do you live outside Barcelona but would like to be treated at the Institut de la Màcula? Enter here and find all the information you need.

Institut channel Follow us on YouTube

Last modified 23 July, 2016 - 11:07